146 related articles for article (PubMed ID: 12878866)
21. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
Ader I; Toulas C; Dalenc F; Delmas C; Bonnet J; Cohen-Jonathan E; Favre G
Oncogene; 2002 Sep; 21(39):5998-6006. PubMed ID: 12203112
[TBL] [Abstract][Full Text] [Related]
22. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities.
Feldkamp MM; Lau N; Guha A
Ann N Y Acad Sci; 1999; 886():257-60. PubMed ID: 10667233
[No Abstract] [Full Text] [Related]
23. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
[No Abstract] [Full Text] [Related]
24. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
Ohkanda J
Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
[No Abstract] [Full Text] [Related]
25. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
Delmas C; Heliez C; Cohen-Jonathan E; End D; Bonnet J; Favre G; Toulas C
Int J Cancer; 2002 Jul; 100(1):43-8. PubMed ID: 12115585
[TBL] [Abstract][Full Text] [Related]
26. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
Schlitzer M
Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
[No Abstract] [Full Text] [Related]
27. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitors: promises and realities.
Cox AD; Der CJ
Curr Opin Pharmacol; 2002 Aug; 2(4):388-93. PubMed ID: 12127871
[TBL] [Abstract][Full Text] [Related]
29. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.
Sebti SM; Der CJ
Nat Rev Cancer; 2003 Dec; 3(12):945-51. PubMed ID: 14737124
[No Abstract] [Full Text] [Related]
30. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
31. Isolation of farnesyltransferase inhibitors from herbal medicines.
Kwon BM; Lee SH; Kim MJ; Kim HK; Kim HM
Ann N Y Acad Sci; 1999; 886():261-4. PubMed ID: 10667234
[No Abstract] [Full Text] [Related]
32. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
33. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
34. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
36. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
37. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2003; 21():127-44. PubMed ID: 15338743
[No Abstract] [Full Text] [Related]
39. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
40. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.
Baron R; Fourcade E; Lajoie-Mazenc I; Allal C; Couderc B; Barbaras R; Favre G; Faye JC; Pradines A
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11626-31. PubMed ID: 11027361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
